Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.23
LCI's Cash to Debt is ranked lower than
85% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. LCI: 0.23 )
Ranked among companies with meaningful Cash to Debt only.
LCI' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 2.40 Max: N/A
Current: 0.23
Equity to Asset 0.31
LCI's Equity to Asset is ranked lower than
87% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. LCI: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
LCI' s Equity to Asset Range Over the Past 10 Years
Min: -0.17  Med: 0.71 Max: 0.92
Current: 0.31
-0.17
0.92
Interest Coverage 3.89
LCI's Interest Coverage is ranked lower than
79% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.86 vs. LCI: 3.89 )
Ranked among companies with meaningful Interest Coverage only.
LCI' s Interest Coverage Range Over the Past 10 Years
Min: 23.42  Med: 47.21 Max: 1094.14
Current: 3.89
23.42
1094.14
F-Score: 4
Z-Score: 1.50
M-Score: 1.82
WACC vs ROIC
19.68%
14.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 32.01
LCI's Operating margin (%) is ranked higher than
93% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. LCI: 32.01 )
Ranked among companies with meaningful Operating margin (%) only.
LCI' s Operating margin (%) Range Over the Past 10 Years
Min: -7.5  Med: 9.74 Max: 55.67
Current: 32.01
-7.5
55.67
Net-margin (%) 15.89
LCI's Net-margin (%) is ranked higher than
82% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.02 vs. LCI: 15.89 )
Ranked among companies with meaningful Net-margin (%) only.
LCI' s Net-margin (%) Range Over the Past 10 Years
Min: -8.39  Med: 5.87 Max: 36.85
Current: 15.89
-8.39
36.85
ROE (%) 15.10
LCI's ROE (%) is ranked higher than
74% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. LCI: 15.10 )
Ranked among companies with meaningful ROE (%) only.
LCI' s ROE (%) Range Over the Past 10 Years
Min: -9.5  Med: 7.88 Max: 39.56
Current: 15.1
-9.5
39.56
ROA (%) 7.49
LCI's ROA (%) is ranked higher than
70% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. LCI: 7.49 )
Ranked among companies with meaningful ROA (%) only.
LCI' s ROA (%) Range Over the Past 10 Years
Min: -6.58  Med: 5.22 Max: 35.21
Current: 7.49
-6.58
35.21
ROC (Joel Greenblatt) (%) 47.55
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.79 vs. LCI: 47.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LCI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12.51  Med: 24.64 Max: 133.35
Current: 47.55
-12.51
133.35
Revenue Growth (3Y)(%) 36.30
LCI's Revenue Growth (3Y)(%) is ranked higher than
92% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. LCI: 36.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LCI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 17.10 Max: 79.1
Current: 36.3
-3.7
79.1
EBITDA Growth (3Y)(%) 141.90
LCI's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. LCI: 141.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LCI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -92  Med: 36.80 Max: 153.4
Current: 141.9
-92
153.4
EPS Growth (3Y)(%) 206.70
LCI's EPS Growth (3Y)(%) is ranked higher than
98% of the 509 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. LCI: 206.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LCI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.1  Med: 14.40 Max: 206.7
Current: 206.7
-58.1
206.7
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

LCI Guru Trades in Q2 2015

Chuck Royce 429,281 sh (+176.10%)
Joel Greenblatt 1,728,019 sh (+11.07%)
Steven Cohen Sold Out
Paul Tudor Jones 4,619 sh (-64.35%)
» More
Q3 2015

LCI Guru Trades in Q3 2015

David Dreman 367 sh (New)
John Hussman 133,000 sh (New)
Paul Tudor Jones 20,657 sh (+347.22%)
Joel Greenblatt 1,397,853 sh (-19.11%)
Chuck Royce 346,391 sh (-19.31%)
» More
Q4 2015

LCI Guru Trades in Q4 2015

John Hussman Sold Out
Chuck Royce Sold Out
David Dreman Sold Out
Joel Greenblatt 1,121,673 sh (-19.76%)
Paul Tudor Jones 16,538 sh (-19.94%)
» More
Q1 2016

LCI Guru Trades in Q1 2016

Jim Simons 21,500 sh (New)
David Dreman 70 sh (New)
Ronald Muhlenkamp 406,600 sh (New)
Richard Snow 174,065 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:SUPN, OTCPK:CSWYY, OTCPK:GNMLF, NAS:MNTA, NAS:AMPH, NAS:SGYP, NAS:SCLN, NAS:ACET, OTCPK:KHTRF, NAS:HRTX, NAS:DEPO, NAS:EGRX, OTCPK:EVTCY, NAS:CPXX, NAS:SGNT, NAS:SCMP, NAS:LBIO, OTCPK:CVNZF, NAS:PCRX, NAS:ADMS » details
Traded in other countries:LN5.Germany,
Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Lannett Co Inc was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. The Company manufactures solid oral dosage forms, including tablets and capsules, extended release, topicals, oral solutions and distributes parenteral as well as ophthalmics. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories Synthroid(r) and Monarch Pharmaceuticals Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, ma

Top Ranked Articles about Lannett Co Inc

A Short-Term Problem Creates Long-Term Opportunity in Lannett Company Generic drug manufacturer is mispriced due to irrational fears
I use several different techniques to search for potential investment opportunities. But, there is no question that I strongly favor value investing because I like large margins of safety surrounding my money. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 12.31
LCI's P/E(ttm) is ranked higher than
84% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.34 vs. LCI: 12.31 )
Ranked among companies with meaningful P/E(ttm) only.
LCI' s P/E(ttm) Range Over the Past 10 Years
Min: 7.92  Med: 25.29 Max: 222.5
Current: 12.31
7.92
222.5
Forward P/E 7.52
LCI's Forward P/E is ranked higher than
89% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. LCI: 7.52 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 12.31
LCI's PE(NRI) is ranked higher than
83% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.24 vs. LCI: 12.31 )
Ranked among companies with meaningful PE(NRI) only.
LCI' s PE(NRI) Range Over the Past 10 Years
Min: 7.92  Med: 25.29 Max: 222.5
Current: 12.31
7.92
222.5
Price/Owner Earnings (ttm) 8.29
LCI's Price/Owner Earnings (ttm) is ranked higher than
91% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.00 vs. LCI: 8.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LCI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.44  Med: 18.51 Max: 834.91
Current: 8.29
4.44
834.91
P/B 1.63
LCI's P/B is ranked higher than
70% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. LCI: 1.63 )
Ranked among companies with meaningful P/B only.
LCI' s P/B Range Over the Past 10 Years
Min: 0.61  Med: 1.72 Max: 6.39
Current: 1.63
0.61
6.39
P/S 1.94
LCI's P/S is ranked higher than
61% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. LCI: 1.94 )
Ranked among companies with meaningful P/S only.
LCI' s P/S Range Over the Past 10 Years
Min: 0.48  Med: 1.54 Max: 7.05
Current: 1.94
0.48
7.05
PFCF 6.71
LCI's PFCF is ranked higher than
89% of the 189 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.95 vs. LCI: 6.71 )
Ranked among companies with meaningful PFCF only.
LCI' s PFCF Range Over the Past 10 Years
Min: 3.22  Med: 22.78 Max: 526.92
Current: 6.71
3.22
526.92
POCF 5.65
LCI's POCF is ranked higher than
88% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.49 vs. LCI: 5.65 )
Ranked among companies with meaningful POCF only.
LCI' s POCF Range Over the Past 10 Years
Min: 2.89  Med: 16.67 Max: 274.76
Current: 5.65
2.89
274.76
EV-to-EBIT 11.35
LCI's EV-to-EBIT is ranked higher than
74% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. LCI: 11.35 )
Ranked among companies with meaningful EV-to-EBIT only.
LCI' s EV-to-EBIT Range Over the Past 10 Years
Min: -259.1  Med: 10.70 Max: 348.4
Current: 11.35
-259.1
348.4
EV-to-EBITDA 9.95
LCI's EV-to-EBITDA is ranked higher than
74% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.28 vs. LCI: 9.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
LCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2299.1  Med: 10.10 Max: 681
Current: 9.95
-2299.1
681
PEG 0.15
LCI's PEG is ranked higher than
98% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. LCI: 0.15 )
Ranked among companies with meaningful PEG only.
LCI' s PEG Range Over the Past 10 Years
Min: 0.07  Med: 0.53 Max: 109.79
Current: 0.15
0.07
109.79
Shiller P/E 32.56
LCI's Shiller P/E is ranked higher than
66% of the 149 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.12 vs. LCI: 32.56 )
Ranked among companies with meaningful Shiller P/E only.
LCI' s Shiller P/E Range Over the Past 10 Years
Min: 23.17  Med: 86.97 Max: 1389
Current: 32.56
23.17
1389
Current Ratio 3.40
LCI's Current Ratio is ranked higher than
64% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. LCI: 3.40 )
Ranked among companies with meaningful Current Ratio only.
LCI' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.45 Max: 10.52
Current: 3.4
0.99
10.52
Quick Ratio 2.74
LCI's Quick Ratio is ranked higher than
65% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. LCI: 2.74 )
Ranked among companies with meaningful Quick Ratio only.
LCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.72 Max: 9.3
Current: 2.74
0.26
9.3
Days Inventory 140.62
LCI's Days Inventory is ranked lower than
64% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.06 vs. LCI: 140.62 )
Ranked among companies with meaningful Days Inventory only.
LCI' s Days Inventory Range Over the Past 10 Years
Min: 68.82  Med: 108.00 Max: 165.34
Current: 140.62
68.82
165.34
Days Sales Outstanding 141.73
LCI's Days Sales Outstanding is ranked lower than
84% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.75 vs. LCI: 141.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
LCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.9  Med: 98.94 Max: 171.98
Current: 141.73
78.9
171.98
Days Payable 62.04
LCI's Days Payable is ranked lower than
57% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.79 vs. LCI: 62.04 )
Ranked among companies with meaningful Days Payable only.
LCI' s Days Payable Range Over the Past 10 Years
Min: 8.23  Med: 74.51 Max: 88.36
Current: 62.04
8.23
88.36

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.85
LCI's Price/Projected FCF is ranked higher than
87% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. LCI: 0.85 )
Ranked among companies with meaningful Price/Projected FCF only.
LCI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.43 Max: 5.6
Current: 0.85
0.57
5.6
Price/Median PS Value 1.21
LCI's Price/Median PS Value is ranked lower than
59% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. LCI: 1.21 )
Ranked among companies with meaningful Price/Median PS Value only.
LCI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 1.22 Max: 7.21
Current: 1.21
0.44
7.21
Price/Peter Lynch Fair Value 0.47
LCI's Price/Peter Lynch Fair Value is ranked higher than
92% of the 172 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.44 vs. LCI: 0.47 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LCI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.36  Med: 1.24 Max: 15.96
Current: 0.47
0.36
15.96
Earnings Yield (Greenblatt) (%) 8.78
LCI's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. LCI: 8.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LCI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 7.60 Max: 37.4
Current: 8.78
0.3
37.4
Forward Rate of Return (Yacktman) (%) 126.87
LCI's Forward Rate of Return (Yacktman) (%) is ranked higher than
99% of the 326 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.89 vs. LCI: 126.87 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LCI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -12  Med: 4.30 Max: 128.7
Current: 126.87
-12
128.7

More Statistics

Revenue (TTM) (Mil) $472.9
EPS (TTM) $ 2.01
Beta2.43
Short Percentage of Float36.08%
52-Week Range $16.91 - 62.90
Shares Outstanding (Mil)36.75

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 558 682 719 742
EPS ($) 3.18 3.13 3.31 3.60
EPS w/o NRI ($) 3.18 3.13 3.31 3.60
EPS Growth Rate
(3Y to 5Y Estimate)
102.00%
» More Articles for NYSE:LCI

Headlines

Articles On GuruFocus.com
Snow Capital Management's Top 5 New Buys May 12 2016 
A Short-Term Problem Creates Long-Term Opportunity in Lannett Company Jan 12 2016 
Healthcare Company Lannett Offers Compelling Value Oct 13 2015 
Royce 100 Fund Shareholder Letter Sep 20 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 
Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 
Lannett Company Inc Reports Operating Results (10-K) Sep 24 2010 
Lannett Company Inc Reports Operating Results (10-Q) May 13 2010 
Lannett Company Inc Reports Operating Results (10-Q) Feb 11 2010 

More From Other Websites
Coverage initiated on Lannett by Deutsche Bank Jun 29 2016
Lannett Receives FDA Approval For Diazepam Oral Solution, 5 mg/5 mL Jun 28 2016
Lannett Receives FDA Approval For Diazepam Oral Solution, 5 mg/5 mL Jun 28 2016
LANNETT CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Jun 20 2016
Lannett Completes Repurchase Of Remaining $200 Million Of 12% Senior Notes Jun 20 2016
Lannett Completes Repurchase Of Remaining $200 Million Of 12% Senior Notes Jun 20 2016
$200M buyback: Lannett wiping more high-interest debt off its balance sheet Jun 14 2016
Lannett To Amend Credit Agreement To Repurchase Remaining $200 Million Of 12% Senior Notes Jun 14 2016
Lannett To Amend Credit Agreement To Repurchase Remaining $200 Million Of 12% Senior Notes Jun 14 2016
LANNETT CO INC Files SEC form 8-K, Regulation FD Disclosure Jun 13 2016
Lannett Gets FDA Approval For Neomycin Sulfate Tablets Jun 13 2016
Lannett Receives FDA Approval For Neomycin Sulfate Tablets USP, 500 mg Jun 13 2016
Lannett Receives FDA Approval For Neomycin Sulfate Tablets USP, 500 mg Jun 13 2016
This Winning Investing Strategy Defies Logic Jun 09 2016
Do Charts Agree With Bears on the Most-Shorted Stocks? Jun 09 2016
LANNETT CO INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 27 2016
Lannett Completes $50 Million-Pay Down Of 12% Senior Notes May 27 2016
Lannett Completes $50 Million-Pay Down Of 12% Senior Notes May 27 2016
Lannett To Voluntarily Pay Down $50 Million Of 12% Senior Notes May 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)